The Korea Disease Control and Prevention Agency (KDCA) is launching an expanded Rare Disease Diagnosis Support Program in 2026 to address the challenges faced by patients and families awaiting rare disease diagnoses. Rare diseases often require an average of 9.2 years for accurate diagnosis, causing prolonged suffering and delayed access to treatment and financial support. The program aims to facilitate early diagnosis through genetic testing and interpretation, connecting patients to timely care and relevant national support systems. This initiative aligns with Korea’s national policy to reduce medical expenses for rare and intractable diseases.
The expanded program will impact suspected rare disease patients and their families, offering diagnostic support to 1,150 individuals in 2026, up from 810 in 2025. Coverage will include 1,389 rare diseases, an increase of 75 from the previous year. Family members of patients diagnosed with genetic rare diseases, such as parents and siblings, will also receive additional testing support, targeting high-risk groups. The program continues to prioritize early diagnosis for conditions like spinal muscular atrophy (SMA), with ongoing screening and confirmatory testing.
Implementation will be carried out through 34 participating medical institutions nationwide, including both metropolitan and non-metropolitan areas. The program’s expansion represents a 42% increase in patient coverage compared to 2025, but ongoing demand analysis suggests further growth may be needed. Diagnostic support information, including eligibility and participating institutions, will be accessible from March 31, 2026, via the KDCA Rare Disease Helpline. The program also includes provisions for re-analysis of unresolved cases in collaboration with the National Institute of Health.
Frequently asked questions include: Who can access the program? Suspected rare disease patients and their families can receive support at nearby participating medical institutions. What are the benefits? Early genetic diagnosis, family testing, and linkage to financial aid and treatment programs. How long does diagnosis take? In 2025, the average time from genetic testing to result was 26 days. What is the satisfaction rate? Patient and family satisfaction was 95%, and medical staff satisfaction was 94%, indicating high trust and effectiveness.
Metaqsol opinion: The KDCA’s expanded Rare Disease Diagnosis Support Program is a significant step toward improving early detection and reducing the burden on patients and families. The increase in coverage and inclusion of more diseases and family testing reflects a targeted response to diagnostic delays and unmet needs. High satisfaction rates indicate strong trust in the program, and ongoing expansion will be crucial to address persistent demand. The integration with financial support and national health policies enhances the program’s impact and accessibility.